Altimmune, Inc., a clinical-stage immunotherapeutics biotechnology company, announced it will relocate new employees acquired because of its merger with Pharmathene, as well as its existing Gaithersburg employees, to a new 14,000 square-foot location in Gaithersburg. The new, larger location at 910 Clopper Road will include the company’s research and development facility, and the move is expected to be completed by the first quarter of 2018. Altimmune currently has 14 full-time employees in Gaithersburg. The expansion will add 45 new jobs over the next four years.
Altimmune designs and develops immunotherapeutic products tailored to address a wide range of diseases, including acute respiratory infections, chronic viral infections, and cancer. The company’s lead product, NasoVAX, an intranasally administered recombinant flu vaccine, is expected to begin Phase 2 development in the coming weeks. HepTcell, the company’s second clinical program, is an immunotherapy for treating patients chronically infected with the Hepatitis B virus. The company’s two complementary fully government-sponsored anthrax vaccine programs, SparVax-L and NasoShield, are ongoing with continued updates and data announcements expected in 2018.
To assist with project costs, the Maryland Department of Commerce has approved a $150,000 conditional loan through the Maryland Economic Development Assistance Authority and Fund (MEDAAF). In addition, Montgomery County is providing a $100,000 conditional grant through its Economic Development Fund. The company is also eligible for a grant up to $50,000 from the City of Gaithersburg’s Economic Development Toolbox Program, as well as various state and local tax credits, including Maryland’s Job Creation Tax Credit.
To learn more about career opportunities with the company, visit www.altimmune.com.
Read the full press release from MD Department of Commerce.
